MAPK7 and non-small cell lung carcinoma: Notably, in NSCLC patients MEK5-ERK5 signalling is often upregulated and correlates with poor patient survival (Sanchez-Fdez et al, 2021), thus these patients are expected to exhibit inherent FAK inhibitor resistance, providing additional rationale for the use of MEK5 or ERK5 inhibitors in the clinic.